Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 26, 2011 ISIS, IDRA, IDIX, HLCS, HEB, GTXI, Biomed - Genetics Stocks 5.46% undervalued
January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. ISIS PHARMACEUTICALS INC (NASDAQ:ISIS), IDERA PHARMACEUTICALS INC (NASDAQ:IDRA), IDENIX PHARMACEUTICALS INC (NASDAQ:IDIX), HELICOS BIOSCIENCES CORP (OTC:HLCS), HEMISPHERX BIOPHARMA INC (AMEX:HEB), GTX INC (NASDAQ:GTXI) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.
The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:
Symbol Company Name Last Close Fair Value Valuation Industry
ISIS ISIS PHARMACEUTICALS INC 9.26 9.8 5.46% undervalued Biomed - Genetics
IDRA IDERA PHARMACEUTICALS INC 2.78 11.12 75.00% undervalued Biomed - Genetics
IDIX IDENIX PHARMACEUTICALS INC 4.64 6.16 24.73% undervalued Biomed - Genetics
HLCS HELICOS BIOSCIENCES CORP 0.16 1.28 87.50% undervalued Biomed - Genetics
HEB HEMISPHERX BIOPHARMA INC 0.5005 1.07 53.17% undervalued Biomed - Genetics
GTXI GTX INC 2.94 11.76 75.00% undervalued Biomed - Genetics
Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.
Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.
ISIS PHARMACEUTICALS INC (NASDAQ:ISIS) - Isis Pharmaceuticals, Inc. engages in the discovery and development of a new class of drugs called antisense drugs using antisense technology, a novel drug discovery platform to generate a broad pipeline of first-in-class drugs. It develops antisense drugs focused on treating cardiovascular, metabolic and severe neurodegenerative diseases, and cancer for systemic, local, and inhaled delivery. The company has commercialized antisense drugs and has 22 drugs in development. Isis Pharmaceuticals has strategic alliances with GlaxoSmithKline, Genzyme Corporation, Archemix Corp., and Alnylam Pharmaceuticals, Inc. The company was founded in 1989 and is based in Carlsbad, California.
IDERA PHARMACEUTICALS INC (NASDAQ:IDRA) - Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimers disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.
IDENIX PHARMACEUTICALS INC (NASDAQ:IDIX) - Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company primarily focuses its research and development on the treatment for hepatitis C virus. The company develops nucleoside/nucleotide polymerase inhibitors, including IDX184, a liver-targeted nucleotide prodrug candidate, which is in phase IIa clinical trial; and IDX102 that completed late-stage preclinical development. It also develops IDX375, a novel palm-binding polymerase inhibitor that is in phase I program; IDX320, a protease inhibitor candidate, which is in phase I healthy volunteer clinical study; and NS5A inhibitors. In addition, the company licensed its telbivudine (Tyzeka/Sebivo), a drug for the treatment of hepatitis B virus, to Novartis Pharma AG; and GSK2248761, a drug candidate from the class of compounds known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of human immunodeficiency virus type 1 and acquired immune deficiency syndrome to GlaxoSmithKline. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
HELICOS BIOSCIENCES CORP (OTC:HLCS) - Helicos BioSciences Corporation, a life sciences company, focuses on the genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets primarily in the United States. Its proprietary True Single Molecule Sequencing technology enables the analysis of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. The companys Helicos genetic analysis platform consists of HeliScope single molecule sequencer; HeliScope analysis engine, an image analysis computer tower; associated reagents, which are chemicals used in the sequencing process; and disposable supplies. Its Helicos genetic analysis system is used for various applications in the areas of studying the human genome, disease association studies, molecular diagnostics, cancer research, pharmaceutical research and development, infectious diseases, autoimmune conditions, and agricultural research. The company was formerly known as Newco LS6, Inc. and changed its name to Helicos BioSciences Corporation in November 2003. Helicos BioSciences Corporation was founded in 2003 and is headquartered in Cambridge, Massachusetts.
HEMISPHERX BIOPHARMA INC (AMEX:HEB) - Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The companys products include Ampligen, an experimental drug that is under clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, Hepatitis B, human immunodeficiency virus, renal cell carcinoma, and malignant melanoma; and Alferon N Injection for the treatment of genital warts. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of chronic viral and immunological disorders. The company has a strategic alliance with Accredo to develop certain marketing and distribution capacities for Ampligen in the United States. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
GTX INC (NASDAQ:GTXI) - GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors in the United States. It is developing Toremifene citrate 80 mg, which completed pivotal Phase III clinical trial to reduce fractures and treat other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and Toremifene 20 mg that is in pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia. The company is also developing selective androgen receptor modulators comprising Ostarine, which completed Phase II clinical trials for the treatment of cancer cachexia and chronic sarcopenia; and GTx-758, an oral luteinizing hormone that completed two Phase I clinical trials for the treatment of advanced prostate cancer. It has a partnership agreement with Ipsen S.A. for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy and toremifene 20 mg for the prevention of prostate cancer in patients with high grade prostatic intraepithelial neoplasia lesions. GTx, Inc. was founded in 1997 and is headquartered Memphis, Tennessee.
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
Contact:
BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net
- WOPRAI
- support@woprai.com